Company profile
BioXcel Therapeutics, Inc.
NASDAQ: BTAI · Healthcare · Biotechnology
#911 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
27DFH 17DQ 31GM 37SS 46
v0.1 · 65/100 weight · provisional
↑ 3-yr revenue growth, market scale · ↓ net margin, operating margin
Methodology →Revenue TTM
$742.0k
Rev growth YoY (TTM)
-14.5%
Net income (FY)
-$69.9M
Employees
29
as of 2026-08-20
Market cap
$25.5M
as of 2026-08-20
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$642.0k$642.0k2025
Net income-$69.9M-$69.9M2025
Operating income-$50.5M-$50.5M2025
Total assets$44.9M$44.9M2025
Liabilities$140.4M$140.4M2025
Equity-$95.5M-$95.5M2025
Revenue trend
FY2022 – FY2025 · USD
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is BioXcel Therapeutics, Inc.’s revenue?
BioXcel Therapeutics, Inc. booked $642.0k in FY2025 revenue, contracting 72% year over year — slower than 86% of Healthcare companies we track, at a -10887.4% net margin.
Peers · Healthcare
Lexeo Therapeutics, Inc. Common Stock37DPolomar Health Services, Inc.28DMarizyme, Inc.——Comera Life Sciences Holdings, Inc.——CEN Biotech, Inc.——Co-Diagnostics, Inc.33DNeighbors
New Haven →Key facts
CEOVimal D. Mehta
SectorHealthcare
IndustryBiotechnology
HeadquartersNew Haven, CT
ExchangeNASDAQ: BTAI
Employees29
IPO date2018-03-08
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.